Skip Nav Destination
Issues
1 January 2012
-
Cover Image
Cover Image
Wagle and colleagues describe a method to profile clinically relevant mutations in formalin-fixed, paraffin-embedded tumor samples involving exon capture of frequently mutated or polymorphic genes followed by massively parallel sequencing. This method identifies single-nucleotide variants, insertions, deletions, and copy number alterations overlooked by current genotyping-based methods with high specificity and sensitivity. Identification of such “actionable” genetic alterations that predict response to targeted or conventional cytotoxic therapies has the potential to facilitate individualized cancer treatment in a time- and cost-effective manner. For details, please see the article by Wagle and colleagues on page 82. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Editorial
In This Issue
In the Spotlight
Review
Research Briefs
ATM Mutations in Patients with Hereditary Pancreatic Cancer
Nicholas J. Roberts; Yuchen Jiao; Jun Yu; Levy Kopelovich; Gloria M. Petersen; Melissa L. Bondy; Steven Gallinger; Ann G. Schwartz; Sapna Syngal; Michele L. Cote; Jennifer Axilbund; Richard Schulick; Syed Z. Ali; James R. Eshleman; Victor E. Velculescu; Michael Goggins; Bert Vogelstein; Nickolas Papadopoulos; Ralph H. Hruban; Kenneth W. Kinzler; Alison P. Klein
Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation
Oliver Weigert; Nadja Kopp; Andrew A. Lane; Akinori Yoda; Suzanne E. Dahlberg; Donna Neuberg; Anita Y. Bahar; Bjoern Chapuy; Jeffery L. Kutok; Janina A. Longtine; Frank C. Kuo; Terry Haley; Maura Salois; Timothy J. Sullivan; David C. Fisher; Edward A. Fox; Scott J. Rodig; Joseph H. Antin; David M. Weinstock
Research Articles
Genomic Complexity and AKT Dependence in Serous Ovarian Cancer
Aphrothiti J. Hanrahan; Nikolaus Schultz; Maggie L. Westfal; Rita A. Sakr; Dilip D. Giri; Stefano Scarperi; Manickam Janikariman; Narciso Olvera; Ellen V. Stevens; Qing-Bai She; Carol Aghajanian; Tari A. King; Elisa de Stanchina; David R. Spriggs; Adriana Heguy; Barry S. Taylor; Chris Sander; Neal Rosen; Douglas A. Levine; David B. Solit
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Nikhil Wagle; Michael F. Berger; Matthew J. Davis; Brendan Blumenstiel; Matthew DeFelice; Panisa Pochanard; Matthew Ducar; Paul Van Hummelen; Laura E. MacConaill; William C. Hahn; Matthew Meyerson; Stacey B. Gabriel; Levi A. Garraway
News in Brief
News in Depth
Research Watch
Angiogenesis
Breast Cancer
Clinical Trials
Drug Resistance
Gene Therapy
Imaging
Metabolism
Pathology
Tumor Microenvironment
Tumor Suppressors
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.